Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Mock, A., Warta, R., Geisenberger, C., Bischoff, R., Schulte, A., Lamszus, K., Stadler, V., Felgenhauer, T., Schichor, C., Schwartz, C., Matschke, J., Jungk, C., Ahmadi, R., Sahm, F., Capper, D., Glass, R., Tonn, J., Westphal, M., von Deimling, A., Unterberg, A., Bermejo, J. L., & Herold-Mende, C. Oncotarget, May, 2015. Number: 15![Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex 1 download Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p\textless0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.
@article{mock_printed_2015,
title = {Printed peptide arrays identify prognostic {TNC} serumantibodies in glioblastoma patients},
volume = {6},
issn = {1949-2553},
url = {http://www.oncotarget.com/fulltext/3791},
doi = {10.18632/oncotarget.3791},
abstract = {Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p{\textless}0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.},
language = {en},
number = {15},
urldate = {2019-11-28},
journal = {Oncotarget},
author = {Mock, Andreas and Warta, Rolf and Geisenberger, Christoph and Bischoff, Ralf and Schulte, Alexander and Lamszus, Katrin and Stadler, Volker and Felgenhauer, Thomas and Schichor, Christian and Schwartz, Christoph and Matschke, Jakob and Jungk, Christine and Ahmadi, Rezvan and Sahm, Felix and Capper, David and Glass, Rainer and Tonn, Jörg-Christian and Westphal, Manfred and von Deimling, Andreas and Unterberg, Andreas and Bermejo, Justo Lorenzo and Herold-Mende, Christel},
month = may,
year = {2015},
note = {Number: 15},
keywords = {Accessories, Application - Antibody Validation / Epitope Mapping, Application - Biomarker Discovery, Application - Cancer Research, Country - Germany, Human, PEPperCHIP - Customized - Linear, Sample Type - Serum},
}
Downloads: 1
{"_id":"QwxbTBTmRZrydXZQx","bibbaseid":"mock-warta-geisenberger-bischoff-schulte-lamszus-stadler-felgenhauer-etal-printedpeptidearraysidentifyprognostictncserumantibodiesinglioblastomapatients-2015","authorIDs":[],"author_short":["Mock, A.","Warta, R.","Geisenberger, C.","Bischoff, R.","Schulte, A.","Lamszus, K.","Stadler, V.","Felgenhauer, T.","Schichor, C.","Schwartz, C.","Matschke, J.","Jungk, C.","Ahmadi, R.","Sahm, F.","Capper, D.","Glass, R.","Tonn, J.","Westphal, M.","von Deimling, A.","Unterberg, A.","Bermejo, J. L.","Herold-Mende, C."],"bibdata":{"bibtype":"article","type":"article","title":"Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients","volume":"6","issn":"1949-2553","url":"http://www.oncotarget.com/fulltext/3791","doi":"10.18632/oncotarget.3791","abstract":"Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p\\textless0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.","language":"en","number":"15","urldate":"2019-11-28","journal":"Oncotarget","author":[{"propositions":[],"lastnames":["Mock"],"firstnames":["Andreas"],"suffixes":[]},{"propositions":[],"lastnames":["Warta"],"firstnames":["Rolf"],"suffixes":[]},{"propositions":[],"lastnames":["Geisenberger"],"firstnames":["Christoph"],"suffixes":[]},{"propositions":[],"lastnames":["Bischoff"],"firstnames":["Ralf"],"suffixes":[]},{"propositions":[],"lastnames":["Schulte"],"firstnames":["Alexander"],"suffixes":[]},{"propositions":[],"lastnames":["Lamszus"],"firstnames":["Katrin"],"suffixes":[]},{"propositions":[],"lastnames":["Stadler"],"firstnames":["Volker"],"suffixes":[]},{"propositions":[],"lastnames":["Felgenhauer"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Schichor"],"firstnames":["Christian"],"suffixes":[]},{"propositions":[],"lastnames":["Schwartz"],"firstnames":["Christoph"],"suffixes":[]},{"propositions":[],"lastnames":["Matschke"],"firstnames":["Jakob"],"suffixes":[]},{"propositions":[],"lastnames":["Jungk"],"firstnames":["Christine"],"suffixes":[]},{"propositions":[],"lastnames":["Ahmadi"],"firstnames":["Rezvan"],"suffixes":[]},{"propositions":[],"lastnames":["Sahm"],"firstnames":["Felix"],"suffixes":[]},{"propositions":[],"lastnames":["Capper"],"firstnames":["David"],"suffixes":[]},{"propositions":[],"lastnames":["Glass"],"firstnames":["Rainer"],"suffixes":[]},{"propositions":[],"lastnames":["Tonn"],"firstnames":["Jörg-Christian"],"suffixes":[]},{"propositions":[],"lastnames":["Westphal"],"firstnames":["Manfred"],"suffixes":[]},{"propositions":["von"],"lastnames":["Deimling"],"firstnames":["Andreas"],"suffixes":[]},{"propositions":[],"lastnames":["Unterberg"],"firstnames":["Andreas"],"suffixes":[]},{"propositions":[],"lastnames":["Bermejo"],"firstnames":["Justo","Lorenzo"],"suffixes":[]},{"propositions":[],"lastnames":["Herold-Mende"],"firstnames":["Christel"],"suffixes":[]}],"month":"May","year":"2015","note":"Number: 15","keywords":"Accessories, Application - Antibody Validation / Epitope Mapping, Application - Biomarker Discovery, Application - Cancer Research, Country - Germany, Human, PEPperCHIP - Customized - Linear, Sample Type - Serum","bibtex":"@article{mock_printed_2015,\n\ttitle = {Printed peptide arrays identify prognostic {TNC} serumantibodies in glioblastoma patients},\n\tvolume = {6},\n\tissn = {1949-2553},\n\turl = {http://www.oncotarget.com/fulltext/3791},\n\tdoi = {10.18632/oncotarget.3791},\n\tabstract = {Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p{\\textless}0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.},\n\tlanguage = {en},\n\tnumber = {15},\n\turldate = {2019-11-28},\n\tjournal = {Oncotarget},\n\tauthor = {Mock, Andreas and Warta, Rolf and Geisenberger, Christoph and Bischoff, Ralf and Schulte, Alexander and Lamszus, Katrin and Stadler, Volker and Felgenhauer, Thomas and Schichor, Christian and Schwartz, Christoph and Matschke, Jakob and Jungk, Christine and Ahmadi, Rezvan and Sahm, Felix and Capper, David and Glass, Rainer and Tonn, Jörg-Christian and Westphal, Manfred and von Deimling, Andreas and Unterberg, Andreas and Bermejo, Justo Lorenzo and Herold-Mende, Christel},\n\tmonth = may,\n\tyear = {2015},\n\tnote = {Number: 15},\n\tkeywords = {Accessories, Application - Antibody Validation / Epitope Mapping, Application - Biomarker Discovery, Application - Cancer Research, Country - Germany, Human, PEPperCHIP - Customized - Linear, Sample Type - Serum},\n}\n\n","author_short":["Mock, A.","Warta, R.","Geisenberger, C.","Bischoff, R.","Schulte, A.","Lamszus, K.","Stadler, V.","Felgenhauer, T.","Schichor, C.","Schwartz, C.","Matschke, J.","Jungk, C.","Ahmadi, R.","Sahm, F.","Capper, D.","Glass, R.","Tonn, J.","Westphal, M.","von Deimling, A.","Unterberg, A.","Bermejo, J. L.","Herold-Mende, C."],"key":"mock_printed_2015","id":"mock_printed_2015","bibbaseid":"mock-warta-geisenberger-bischoff-schulte-lamszus-stadler-felgenhauer-etal-printedpeptidearraysidentifyprognostictncserumantibodiesinglioblastomapatients-2015","role":"author","urls":{"Paper":"http://www.oncotarget.com/fulltext/3791"},"keyword":["Accessories","Application - Antibody Validation / Epitope Mapping","Application - Biomarker Discovery","Application - Cancer Research","Country - Germany","Human","PEPperCHIP - Customized - Linear","Sample Type - Serum"],"metadata":{"authorlinks":{}},"downloads":1},"bibtype":"article","biburl":"https://bibbase.org/zotero/PEPperPAPER","creationDate":"2020-09-11T10:12:05.977Z","downloads":1,"keywords":["accessories","application - antibody validation / epitope mapping","application - biomarker discovery","application - cancer research","country - germany","human","pepperchip - customized - linear","sample type - serum"],"search_terms":["printed","peptide","arrays","identify","prognostic","tnc","serumantibodies","glioblastoma","patients","mock","warta","geisenberger","bischoff","schulte","lamszus","stadler","felgenhauer","schichor","schwartz","matschke","jungk","ahmadi","sahm","capper","glass","tonn","westphal","von deimling","unterberg","bermejo","herold-mende"],"title":"Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients","year":2015,"dataSources":["uik5uKfH7ojkHRgZZ","bsHtAr9WnaYGHaqfD","9uWGudyxZThtytFHj","pcAnmugzhzarwnP3W","aphoNEDcQuBnaRkJx","qiu7zqW2xcuf37WKP","RP5CxTRWvKp2zek6s","toHpjkGFdDM9JqudF","yiBnvepfTPGvjnmkb","xRJYNPtGuN7nnbwed","zQuC76ntAG5GnzpKd","vQydgodW2DnvbWLxr","bCft75h4ohnyjY7De","XfqicQ5BW2Zx785GB","BejHfCEEKKZLHTAiJ","iXPxmCb8iG4FtRXEa","9QJhBt6zEQqnhjyEQ","QsdwieyNM5tTaC5Xz","idrrfXaW5AQj5dNMY"]}